Literature DB >> 18506935

Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats.

Sheng Li1, Wan-Chun Wu, Chi-Yi He, Zhen Han, Dao-You Jin, Lin Wang.   

Abstract

AIM: To explore the change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis (NASH) in rats.
METHODS: Thirty-two Sprague-Dawley (SD) rats were randomly divided into control group and model group. Rats in the control group were given normal diet, and rats in the model group were given fat-rich diet. Eight rats in each group were killed at end of the 8th and 12th wk, respectively. The levels of endotoxin, D-xylose, TG, TC, ALT and AST, intestinal tissue SOD and MDA as well as intestinal mucus secretory IgA (sIgA) were measured. The pathology of liver was observed by HE staining.
RESULTS: At end of the 8th wk, there was no marked difference in the levels of endotoxin, D-xylose and sIgA between the two groups. At end of the 12th wk, rats in the model group developed steatohepatitis and had a higher serum level of endotoxin (P = 0.01) and D-xylose (P = 0.00) and a lower serum level of sIgA (P = 0.007).
CONCLUSION: Intestinal mucosa barrier malfunction may exist in NASH rats and may be an important promoter of NASH in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506935      PMCID: PMC2712862          DOI: 10.3748/wjg.14.3254

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Intestinal barrier function.

Authors:  Daniel C Baumgart; Axel U Dignass
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-11       Impact factor: 4.294

2.  Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.

Authors:  K Tomita; G Tamiya; S Ando; K Ohsumi; T Chiyo; A Mizutani; N Kitamura; K Toda; T Kaneko; Y Horie; J-Y Han; S Kato; M Shimoda; Y Oike; M Tomizawa; S Makino; T Ohkura; H Saito; N Kumagai; H Nagata; H Ishii; T Hibi
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

3.  Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease.

Authors:  Jaime Poniachik; Attila Csendes; Juan C Díaz; Jorge Rojas; Patricio Burdiles; Fernando Maluenda; Gladys Smok; Ramón Rodrigo; Luis A Videla
Journal:  Cytokine       Date:  2006-03-27       Impact factor: 3.861

4.  Insulin resistance in NASH.

Authors:  J Choudhury; A J Sanyal
Journal:  Front Biosci       Date:  2005-05-01

5.  Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.

Authors:  Richard Kirsch; Vivian Clarkson; Robert C Verdonk; Adrian D Marais; Enid G Shephard; Bernard Ryffel; Pauline de la M Hall
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

6.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.

Authors:  Stephen A Harrison; Sigurd Torgerson; Paul H Hayashi
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

7.  Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis.

Authors:  Gulden Baskol; Mevlut Baskol; Derya Kocer
Journal:  Clin Biochem       Date:  2007-03-16       Impact factor: 3.281

8.  Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis.

Authors:  Mehmet Koruk; M Cemil Savaş; Omer Yilmaz; Seyithan Tayşi; Metin Karakok; Cemal Gündoğdu; Arif Yilmaz
Journal:  J Clin Gastroenterol       Date:  2003-08       Impact factor: 3.062

Review 9.  Pathogenesis of steatohepatitis: insights from the study of animal models.

Authors:  Isabelle A Leclercq
Journal:  Acta Gastroenterol Belg       Date:  2007 Jan-Mar       Impact factor: 1.316

10.  Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis.

Authors:  Mehmet Koruk; Seyithan Taysi; M Cemil Savas; Omer Yilmaz; Fatih Akcay; Metin Karakok
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

View more
  9 in total

1.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

2.  Effects of intestinal mucosal blood flow and motility on intestinal mucosa.

Authors:  Yan-Bin Wang; Jing Liu; Zhao-Xu Yang
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 3.  Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.

Authors:  Nan Yao; Yixue Yang; Xiaotong Li; Yuxiang Wang; Ruirui Guo; Xuhan Wang; Jing Li; Zechun Xie; Bo Li; Weiwei Cui
Journal:  Front Nutr       Date:  2022-06-17

Review 4.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

Review 5.  Integrated Immunomodulatory Mechanisms through which Long-Chain n-3 Polyunsaturated Fatty Acids Attenuate Obese Adipose Tissue Dysfunction.

Authors:  Danyelle M Liddle; Amber L Hutchinson; Hannah R Wellings; Krista A Power; Lindsay E Robinson; Jennifer M Monk
Journal:  Nutrients       Date:  2017-11-27       Impact factor: 5.717

6.  Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.

Authors:  Li Xue; Juntao He; Ning Gao; Xiaolan Lu; Ming Li; Xiaokang Wu; Zeshi Liu; Yaofeng Jin; Jiali Liu; Jiru Xu; Yan Geng
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

Review 7.  Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Tatsuo Kanda; Taichiro Goto; Yosuke Hirotsu; Ryota Masuzaki; Mitsuhiko Moriyama; Masao Omata
Journal:  Int J Mol Sci       Date:  2020-02-23       Impact factor: 5.923

Review 8.  Immunoglobulin A and liver diseases.

Authors:  Tatsuo Inamine; Bernd Schnabl
Journal:  J Gastroenterol       Date:  2017-10-26       Impact factor: 7.527

9.  Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor.

Authors:  Richard Truse; Steven Grewe; Anna Herminghaus; Jan Schulz; Andreas P M Weber; Tabea Mettler-Altmann; Inge Bauer; Olaf Picker; Christian Vollmer
Journal:  Crit Care       Date:  2019-11-12       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.